Original paper

Formulation and evaluation of niosomal vesicles containing ondansetron HCL for trans-mucosal nasal drug delivery

Volume: 46, Issue: 5, Pages: 751 - 761
Published: Apr 20, 2020
Abstract
Ondansetron HCl is a (5-HT3) serotonin receptor antagonist, used as anti-emetic drug in combination with anticancer agents. Conventional dosage forms have poor bioavailability and patient compliance. These problems can be reduced by the use of nasal niosomal thermo-reversible in situ gelling system. Niosomes were formulated using various surfactants (Span 60, Span 80, Tween 20, and Tween 80) in different ratios using the thin-film hydration...
Paper Details
Title
Formulation and evaluation of niosomal vesicles containing ondansetron HCL for trans-mucosal nasal drug delivery
Published Date
Apr 20, 2020
Volume
46
Issue
5
Pages
751 - 761
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.